Botulinum Toxin Market- Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028
Botulinum Toxin Market |
A byproduct of naturally
occurring Clostridium botulinum bacterium is botulinum toxin. This bacteria can
create the dangerous neurotoxin botulinum toxin and is present in soil and
marine sediments. A "blocking agent," botulinum toxin prevents the
release of several neurotransmitters from the motor nerve terminals,
particularly acetylcholine. Botulinum Toxin comes in around eight different varieties,
ranging from type A to type H. Most commonly employed in cosmetic operations
for the treatment of various face problems, botulinum toxin types A and B are
marketed under the trade name Botox. Additionally, botulinum toxin types A and
B are employed in medical settings to treat a variety of conditions, including
dystonia, recurrent migraines, and spasticity.
The Botulinum
Toxin Market is anticipated to develop in the near future
as a result of frequent approvals of innovative botulinum toxin products for
various indications. For instance, the Dysport (abobotulinumtoxinA) injectable
by Ipsen S.A. was given FDA approval in 2016 and is approved for the treatment
of paediatric lower limb (PLL) spasticity in children two years of age and
older. The FDA granted the business permission to market the same medicine to
adults in 2017. BOTOX Cosmetic (OnabotulinumtoxinA) from Allergan plc got FDA
clearance in 2017 for a new application in forehead wrinkles. The medicine was
previously approved for the treatment of crow's feet lines and glabellar lines.
With this certification, the
manufacturer has broadened the use of its medication to temporarily reduce the
appearance of moderate to severe forehead wrinkles in adults that are caused by
frontalis muscle activity. BOTOX (Botulinum toxin type A) was given the
go-ahead by the U.K.'s Medicines and Healthcare Products Regulatory Agency
(MHRA) in 2014. In the UK, BOTOX has been licenced for the treatment of adult
stroke-related lower limb spasticity-related ankle impairment. In Mexico and
India, Daewoong Pharmaceutical Co., Ltd.'s botulinum toxin Nabota was
authorised in 2016.
Botulinum Toxin Market Applications-
·
Cosmetics
·
Dystonia
·
Chronic Migraines
·
Spasticity
Additionally, the Botulinum Toxin Market
is anticipated to develop in the near future due to the growing trend of using
the toxin in cosmetic operations. For instance, a report from the American
Society of Plastic Surgeons states that in 2016, there were about 7,056,255
cosmetic minimally invasive operations using Botulinum toxin Type A (Botox,
Dysport, and Xeomin), an increase of 4% from 2015. The global Botulinum Toxin Market is anticipated
to rise as more procedures using the toxin and more approved indications are
performed.
Top Companies Involved are- Ipsen group, Allergan Plc., Medytox
Inc., Merz GmbH and Co. KGaA, US Worldmed, LLC, Lanzhou Institute of Biological
Products Co. Ltd., Revance Therapeutics, Inc., and Daewoong Pharmaceutical Co.,
Ltd.
Comments
Post a Comment